Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?

ETFs Show The Sector’s Strength

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ:IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ:XBI) has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.

What makes these numbers remarkable is the journey behind them. Back in April, biotech ETFs hit rock bottom as investors worried about pharmaceutical tariffs. But XBI has since rocketed 75% higher from those lows, touching prices not seen since 2021. That kind of reversal shows real conviction is returning to the space.

Trading activity picked up notably in late December, with both professional money managers and individual investors piling in. Many smaller biotech firms started 2025 running on fumes with under a year of cash left, making them prime targets for larger companies looking to expand their pipelines through acquisitions.

Deal Making Takes Center Stage

Mergers and acquisitions have been the rocket fuel behind this rally. Six of the year’s 10 biggest biopharma deals happened in just the fourth quarter. Johnson & Johnson (NYSE:JNJ) set the tone early by spending $14.6 billion on Intra Cellular Therapies Inc. (NASDAQ:ITCI), signaling that big pharma was ready to write checks.

The real fireworks came in the weight loss drug arena. Pfizer Inc. (NYSE:PFE) ended up paying around $10 billion for Metsera in November, more than double the original $4.9 billion asking price after a bidding war. This GLP-1 feeding frenzy marks a shift away from cancer drugs dominating the M&A landscape.

Novartis AG (NYSE:NVS) dropped $12 billion on Avidity Biosciences Inc. (NASDAQ:RNA), while Merck & Co. Inc. (NYSE:MRK) paid $10 billion for Verona Pharma plc (NASDAQ:VRNA). Analysts expect 2026 to bring even more billion dollar deals, potentially 20 or more.

Here’s why the deals keep coming: major pharmaceutical companies are sitting on over $1.5 trillion in acquisition firepower, according to Tema ETFs research. With 190 drug patents expiring by 2030, these giants need to refill their pipelines fast or watch revenues crater when generic competition arrives.

FDA Approvals Validate Innovation

Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s (NASDAQ:CYTK) Myqorzo for a heart condition, marking the company’s first approval after 27 years in business. Omeros Corporation (NASDAQ:OMER) scored approval for Yartemlea, breaking new ground in treating a rare transplant complication.

The FDA’s supportive stance on cancer and rare disease treatments has helped smooth the approval process. But there’s a catch: the agency cut staff in April, raising questions about whether review timelines might slow down in 2026.

Clinical Wins Drive Stock Surges

Individual companies saw explosive gains tied to trial results. Structure Therapeutics Inc. (NASDAQ:GPCR) more than doubled after its obesity drug showed patients losing over 15% of their weight in trials. Ionis Pharmaceuticals Inc. (NASDAQ:IONS) jumped 120.5% as its pipeline advanced, while Monopar Therapeutics Inc. (NASDAQ:MNPR) soared 185.9% on enthusiasm for its Wilson disease treatment.

The 2026 calendar is packed with potential catalysts. EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) will report results from two major studies on treating vision loss in mid-2026. Eli Lilly and Company (NYSE:LLY) is expected to win approval for its oral GLP-1 pill orforglipron, which crushed its Phase III trials for diabetes and obesity.

Still Room To Run On Valuations

Even after the rally, biotech remains cheap relative to the broader market. The MSCI USA Pharmaceuticals, Biotechnology and Life Sciences Index trades at 15.92 times forward earnings compared to 23.25 times for the overall MSCI USA index as of September. That 15% discount suggests plenty of upside if fundamentals keep improving.

Portfolio managers see multiple tailwinds converging in 2026. Valuations remain reasonable, cancer drug development continues accelerating, and policy winds appear favorable. Key therapeutic areas getting attention include heart and metabolic diseases, brain disorders, cancer treatments, and immune system drugs. Oral GLP-1 medications will be a major focus as companies race to develop pills that can replace injections.

Artificial intelligence is reshaping drug discovery too, helping companies predict which treatments will succeed and speeding up development timelines. This technology advantage is making acquisitions more strategic and efficient.

Watching The Risks

Not everything is sunshine and rainbows. Political uncertainty lingers, especially around drug pricing policies and regulatory changes. While some companies cut pricing deals to avoid tariffs, nobody knows whether those arrangements will stick long term.

Interest rates matter too. The Federal Reserve started cutting rates in September 2025, but expectations for more cuts have cooled. Smaller biotech firms that burn cash and need outside funding would love lower rates, though the sector has shown it can thrive regardless.

The Bottom Line

Biotech’s year-end surge isn’t just hype. Real catalysts are driving gains: companies are getting bought, drugs are getting approved, and clinical trials are delivering results. As 2026 approaches, the setup looks promising with major trial readouts coming, more deal-making expected, and AI accelerating drug development. The sector bounced 75% from April lows and is sitting 15% cheaper than the broader market despite strong growth prospects. Whether the party continues depends on companies executing their clinical programs, acquirers staying disciplined, and regulators keeping the approval process moving. For investors comfortable with biotech’s volatility, the risk-reward equation heading into 2026 looks increasingly attractive.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.